Now in its eighth edition, the event has become a cornerstone for the Kingdom’s efforts to attract investment, foster innovation, and advance the strategic goals of Vision 2030.

The exhibition, held with the support of the Ministry of Health, will highlight Saudi Arabia’s commitment to enhancing healthcare quality, boosting the sector’s contribution to the economy, and establishing the Kingdom as a global hub for healthcare innovation and manufacturing.

Over the next decade, the Saudi healthcare industry is projected to grow significantly, from SR199 billion ($53 billion) in 2020 to SR318 billion by 2030, with private sector contributions expected to double to SR145 billion.

The Ministry of Health has emphasized its focus on creating a competitive investment environment, streamlining regulatory processes, and supporting innovation across critical areas such as biotechnology, pharmaceuticals, vaccine production, health tourism, digital health solutions, and artificial intelligence in healthcare.

These initiatives are designed to accelerate progress toward a self-sufficient, innovation-driven healthcare ecosystem in the Kingdom.

The Global Health Exhibition serves as a vital platform for connecting local and international stakeholders, showcasing the latest medical technologies, and facilitating high-value collaborations.

Last year’s edition generated investments exceeding SR50 billion, including key deals such as the SR4 billion pharmaceutical partnership between NUPCO, Novo Nordisk, and Sanofi, the SR5 billion expansion plan by Fakeeh Care Group, and acquisitions worth over SR4 billion by Dallah Healthcare.

Building on this momentum, the 2025 exhibition is expected to announce new agreements and collaborations in biotechnology, advanced medical technologies, AI-driven healthcare solutions, and digital health platforms.

These developments are expected to further strengthen Saudi Arabia’s position as a regional leader in medical innovation, research, and development, attracting global expertise and investment to the Kingdom.

Experts highlight that the exhibition not only provides a showcase for cutting-edge technology and services but also demonstrates the Kingdom’s commitment to Vision 2030 goals of improving healthcare outcomes, supporting economic diversification, and encouraging private sector growth.

By fostering partnerships in pharmaceuticals, biotech, and healthcare technologies, Saudi Arabia aims to reduce dependency on imports, enhance local manufacturing capabilities, and stimulate job creation in high-value sectors.

The Ministry of Health has also emphasized the role of the exhibition in promoting sustainable growth and innovation, particularly in fields like vaccine production, biotechnology research, digital health solutions, and AI-enabled healthcare tools.

These areas are expected to be central to the Kingdom’s long-term strategy of establishing a world-class healthcare ecosystem that combines technological innovation with high-quality patient care.

Stakeholders anticipate that the event will attract international investors, leading global healthcare companies, and innovative startups, creating opportunities for knowledge exchange, joint ventures, and technology transfer.

The exhibition is expected to highlight Saudi Arabia’s readiness to lead in medical research, biotechnology, and advanced healthcare solutions, reinforcing its role as a hub for global healthcare innovation.

As the Kingdom continues to implement initiatives aligned with Vision 2030, the Global Health Exhibition 2025 represents a critical platform for showcasing achievements, facilitating investment, and strengthening partnerships across the healthcare sector.

By leveraging new technologies, fostering collaboration, and expanding strategic partnerships, Saudi Arabia is well-positioned to enhance healthcare access, improve quality, and secure long-term sustainable growth.

In summary, the upcoming exhibition is set to be a landmark event for Saudi Arabia’s healthcare sector, underlining the Kingdom’s dedication to innovation, investment, and international collaboration.

The announcements and partnerships expected at the event will pave the way for a robust, self-sufficient, and technologically advanced healthcare ecosystem, reflecting Saudi Arabia’s ambition to lead in global healthcare innovation.

The move positions IHH to increase its holding to approximately 57%, marking a significant milestone in its strategic expansion across India’s dynamic healthcare sector.

Investor optimism soars as IHH Healthcare secures regulatory approval for Fortis takeover, signaling strengthened healthcare presence and expansion across India.

IHH (IHHH.KL) climbed 3.1% to 8.38 ringgit ($1.99) on the Malaysian stock exchange, while Fortis (FOHE.NS) soared 6.7% to 1,045.95 rupees, outperforming domestic benchmarks. The gains underscore strong investor confidence and highlight the market’s positive reception of the deal, which has been eagerly anticipated since 2018.

The approval revives a strategic initiative that will strengthen IHH’s operational footprint and enhance healthcare delivery across India. By integrating Fortis’ 33 healthcare facilities, which house over 5,700 beds across 11 states, IHH is set to create a robust network offering high-quality, accessible healthcare to millions of patients nationwide.

Analysts view the approval as a key turning point for both companies. “This milestone signals IHH’s commitment to expanding its presence in India and supporting Fortis in reaching new heights in patient care, medical excellence, and operational efficiency,” noted Nursuhaiza Hashim, equity analyst at BIMB Securities Research.

The successful regulatory clearance is expected to foster long-term value creation for shareholders, employees, and the communities these hospitals serve.

The strategic move also highlights IHH’s growing international footprint. Operating more than 80 hospitals across 10 countries, including Malaysia, Singapore, Türkiye, and India, IHH continues to solidify its position as one of the world’s leading private healthcare providers. The addition of Fortis further strengthens its network, ensuring enhanced healthcare accessibility and world-class medical services across the region.

Fortis, renowned for its high standards in patient care, specialized services, and modern facilities, stands to benefit from IHH’s expertise in operational management and international healthcare best practices. The collaboration between these two healthcare leaders promises a new era of innovation, efficiency, and service quality in India’s growing healthcare market.

Investor enthusiasm reflects confidence in the potential for synergistic growth. Both IHH and Fortis shares have outperformed major indices, signaling strong market sentiment and faith in the long-term benefits of this strategic acquisition. The deal also represents a clear signal to global investors that India’s healthcare sector remains an attractive, high-growth market.

Looking ahead, the expanded IHH-Fortis network is expected to drive improvements in healthcare infrastructure, enhance patient experiences, and facilitate access to cutting-edge treatments and specialized care. The merger positions both companies to take advantage of India’s growing demand for quality healthcare services while delivering sustainable growth and value creation for stakeholders.

This landmark approval is more than just a regulatory milestone—it reflects IHH’s unwavering commitment to strengthening healthcare across India, delivering innovative solutions, and fostering a healthier future for communities nationwide. The strategic integration of Fortis into IHH’s global network demonstrates forward-looking leadership and sets the stage for continued growth and success in the region.

With a strengthened presence and growing capabilities, IHH Healthcare and Fortis are poised to elevate standards of healthcare delivery, ensuring patients across India benefit from world-class medical care while investors enjoy confidence in a robust, forward-looking healthcare ecosystem.